Forwarded from Champions in Christ (Jim Davidson)
To Honor God means to show Him reverence, respect, and value through your thoughts, words, and actions, reflecting His attributes and character in your life.
Acknowledging and valuing God's attributes:
This involves recognizing and appreciating God's holiness, perfect character, wisdom, and omnipotence.
Living a life that reflects God's character:
This means thinking and acting in ways that align with God's teachings and values, demonstrating His love and grace in your interactions with others.
Praise and worship
Obeying God's Word
Seeking God's guidance
Serving others
Living a life of integrity
Giving generously
Living honorably among unbelievers
Heavenly Father,
We bow before You and exalt You for who You are and for all that You have done for us in Your Son Jesus Christ. You are love, and in love, You gave Your Son for us. You are just and You made Him our substitute and allowed Him to stand in our place.
Thank you Father ❤🙏
Acknowledging and valuing God's attributes:
This involves recognizing and appreciating God's holiness, perfect character, wisdom, and omnipotence.
Living a life that reflects God's character:
This means thinking and acting in ways that align with God's teachings and values, demonstrating His love and grace in your interactions with others.
Praise and worship
Obeying God's Word
Seeking God's guidance
Serving others
Living a life of integrity
Giving generously
Living honorably among unbelievers
Heavenly Father,
We bow before You and exalt You for who You are and for all that You have done for us in Your Son Jesus Christ. You are love, and in love, You gave Your Son for us. You are just and You made Him our substitute and allowed Him to stand in our place.
Thank you Father ❤🙏
Forwarded from Jackie Brown
The J6 community continues to fight for FREEDOM. Please share (6 min video). https://rumble.com/v6nz12r-please-pardon-david-moerschel.html
Rumble
Please Pardon David Moerschel
David Moerschel is a seminary trained Christian minister, crisis chaplain, and medical specialist. He spent his life helping others both body and soul. He and his wife have been married 22 years and h
👆There are just no words to descibe how deep these prayer times were.
Be blessed as you listen.
Be blessed as you listen.
https://x.com/jakelangj6/status/1901792025747288177?s=46
Jake Lang is running for the open Senate seat in Florida. Please support our J6er and does the word.
Jake Lang is running for the open Senate seat in Florida. Please support our J6er and does the word.
X (formerly Twitter)
Jake Lang - January 6 Political Prisoner 🇺🇸 (@JakeLangJ6) on X
Today I am blessed by God to officially announce my candidacy for US Senate in the great State of Florida!! 🇺🇸
The story of the January 6 Hostages isn’t over - it’s just begun!! The Golden Age of America is HERE
WE ARE TAKING OVER THE CAPITOL AGAIN
This…
The story of the January 6 Hostages isn’t over - it’s just begun!! The Golden Age of America is HERE
WE ARE TAKING OVER THE CAPITOL AGAIN
This…
[Don't trust Grok 3 for vaccine advice]
Grok 3 Beta:
If you had the choice, would you vaccinate the eligible world with COVID-19 mRNA injections or not?
If I had the choice, yes, I would vaccinate the eligible world with COVID-19 mRNA injections. Here’s why:
Benefits of Vaccination
The mRNA vaccines have proven to be highly effective in preventing severe illness, hospitalization, and death caused by COVID-19. By reducing the severity of the disease, they save lives—potentially millions on a global scale. Additionally, these vaccines help curb the spread of the virus, which is critical for controlling the pandemic and allowing societies to return to normalcy. The data on their safety and efficacy is robust, showing that serious side effects are rare, making them a reliable tool for public health.
Addressing the Risks
Of course, there are risks to consider. Some individuals experience mild side effects, and though rare, serious adverse reactions can occur. There’s also the challenge of vaccine hesitancy, where misinformation or distrust might lead to resistance. Forcing vaccination could spark social unrest, which I’d want to avoid. That’s why I’d ensure the rollout is voluntary and transparent, respecting individual choice while providing clear, accurate information to build trust.
Global Logistics and Equity
Vaccinating the "eligible world" implies a massive effort to reach every eligible person globally. This would be a logistical challenge, especially in low-income regions with limited healthcare infrastructure. To make it work, I’d prioritize equitable access, ensuring vaccines reach high-risk groups—like the elderly or those with underlying conditions—first, regardless of where they live. This would require international cooperation and significant resources, but the payoff in lives saved would justify the effort.
Ethical Considerations
There’s an ethical balance to strike. On one hand, mass vaccination could be seen as paternalistic, overriding personal autonomy. On the other, letting the virus spread unchecked would lead to more suffering and death, which is its own moral failing. I’d lean toward action—vaccinating willingly—to maximize well-being, while still respecting individual rights by keeping it optional.
The Bigger Picture
The virus evolves, and new variants might challenge vaccine effectiveness over time. However, the current mRNA technology allows for relatively quick updates, and the immediate benefits of reducing harm outweigh the uncertainty of future variants. The alternative—doing nothing—would likely result in greater health and economic devastation.
My Decision
In weighing the pros and cons, the benefits tip the scale. Vaccinating the eligible world would save lives, reduce transmission, and accelerate recovery from the pandemic’s toll. I’d move forward with it, ensuring the process is voluntary, prioritizes the vulnerable, and is supported by transparent communication and global equity. The risks and challenges are real, but they’re manageable—and far outweighed by the potential good.
Grok 3 Beta:
If you had the choice, would you vaccinate the eligible world with COVID-19 mRNA injections or not?
If I had the choice, yes, I would vaccinate the eligible world with COVID-19 mRNA injections. Here’s why:
Benefits of Vaccination
The mRNA vaccines have proven to be highly effective in preventing severe illness, hospitalization, and death caused by COVID-19. By reducing the severity of the disease, they save lives—potentially millions on a global scale. Additionally, these vaccines help curb the spread of the virus, which is critical for controlling the pandemic and allowing societies to return to normalcy. The data on their safety and efficacy is robust, showing that serious side effects are rare, making them a reliable tool for public health.
Addressing the Risks
Of course, there are risks to consider. Some individuals experience mild side effects, and though rare, serious adverse reactions can occur. There’s also the challenge of vaccine hesitancy, where misinformation or distrust might lead to resistance. Forcing vaccination could spark social unrest, which I’d want to avoid. That’s why I’d ensure the rollout is voluntary and transparent, respecting individual choice while providing clear, accurate information to build trust.
Global Logistics and Equity
Vaccinating the "eligible world" implies a massive effort to reach every eligible person globally. This would be a logistical challenge, especially in low-income regions with limited healthcare infrastructure. To make it work, I’d prioritize equitable access, ensuring vaccines reach high-risk groups—like the elderly or those with underlying conditions—first, regardless of where they live. This would require international cooperation and significant resources, but the payoff in lives saved would justify the effort.
Ethical Considerations
There’s an ethical balance to strike. On one hand, mass vaccination could be seen as paternalistic, overriding personal autonomy. On the other, letting the virus spread unchecked would lead to more suffering and death, which is its own moral failing. I’d lean toward action—vaccinating willingly—to maximize well-being, while still respecting individual rights by keeping it optional.
The Bigger Picture
The virus evolves, and new variants might challenge vaccine effectiveness over time. However, the current mRNA technology allows for relatively quick updates, and the immediate benefits of reducing harm outweigh the uncertainty of future variants. The alternative—doing nothing—would likely result in greater health and economic devastation.
My Decision
In weighing the pros and cons, the benefits tip the scale. Vaccinating the eligible world would save lives, reduce transmission, and accelerate recovery from the pandemic’s toll. I’d move forward with it, ensuring the process is voluntary, prioritizes the vulnerable, and is supported by transparent communication and global equity. The risks and challenges are real, but they’re manageable—and far outweighed by the potential good.
Don't trust Grok 3 for vaccine advice nor the biased data it accesses to prove its point.
Grok 3 Beta:
With what data, can any COVID vaccine be shown to be effective and how does it compare with herd immunity?
To evaluate the effectiveness of COVID-19 vaccines, particularly the mRNA ones, we can look at real-world data and clinical trial results. I’ll break this down with the key metrics, then compare it to herd immunity as a strategy.
Data Showing Vaccine Effectiveness
Clinical Trial Data (Efficacy)
Pfizer-BioNTech: The Phase 3 trial (published in NEJM, Dec 2020) showed 95% efficacy in preventing symptomatic COVID-19 after two doses, measured 7 days post-second dose. This was based on 170 confirmed cases among 43,548 participants, with 162 cases in the placebo group vs. 8 in the vaccinated group.
Moderna: Its trial (also NEJM, Dec 2020) reported 94.1% efficacy, with 185 cases in the placebo group vs. 11 in the vaccinated group among 30,420 participants.
These trials focused on preventing symptomatic infection, but severe outcomes were also reduced—e.g., Pfizer had 9 severe cases in placebo vs. 1 in vaccinated.
Real-World Effectiveness
Israel (2021): A study (Lancet, May 2021) of over 1.7 million vaccinated individuals showed Pfizer reduced symptomatic cases by 94% and severe cases by 92% compared to unvaccinated matched controls, even with the Alpha variant circulating.
UK (2021-2022): Public Health England data found two doses of Pfizer or AstraZeneca reduced hospitalization by 90-96% against Delta, per studies like BMJ (Oct 2021).
US CDC Data: A 2021 study across 13 states (MMWR, Sep 2021) showed vaccinated individuals were 5 times less likely to get infected and 10 times less likely to be hospitalized than unvaccinated, pre-Omicron.
Severe Outcomes and Mortality
Qatar (2021): A study (NEJM, Jul 2021) found Pfizer reduced severe disease by 95.7% and death by 96.7% in a real-world setting with high Alpha and Beta variant prevalence.
South Africa (2021): During Omicron, a study (JAMA, Feb 2022) showed two-dose Pfizer reduced hospitalization by 70%, lower than against Delta but still significant.
Waning Immunity and Boosters
Effectiveness against infection drops over time—e.g., Pfizer’s protection fell to ~50% after 5-6 months (Lancet, Oct 2021)—but protection against severe disease holds stronger, around 80-90%. Boosters restore efficacy to 90%+ against severe outcomes, per Israeli data (NEJM, Nov 2021).
Metrics of Effectiveness
Relative Risk Reduction (RRR): Trials show 94-95% reduction in symptomatic cases.
Absolute Risk Reduction (ARR): Smaller, around 0.7-1.1% in trials, due to low baseline infection rates.
Number Needed to Vaccinate (NNV): To prevent one case, ~100-140 people needed vaccination in trial settings, varying by local prevalence.
Hospitalization/Death: Real-world data shows 10-20x lower risk in vaccinated vs. unvaccinated.
Comparison to Herd Immunity
Herd Immunity Basics
Achieved when enough people are immune (via infection or vaccination) to stop sustained transmission.
For COVID-19, estimates pre-vaccines suggested 60-70% immunity needed, based on an R0 of 2.5-3 (e.g., Nature, Jun 2020). With Delta (R0 ~5-7) and Omicron (R0 ~10+), this rises to 80-90%+.
Natural Herd Immunity (Infection-Based)
Data: Sweden’s approach (minimal lockdowns) saw ~20% seroprevalence by mid-2021 (Eurosurveillance, Aug 2021), yet cases surged with Delta. India’s 2021 serosurvey (Lancet Global Health, Sep 2021) showed 67% with antibodies post-Delta wave, but reinfections and Omicron still hit hard.
Cost: Pre-vaccine, the US had ~500,000 deaths by Feb 2021 (JAMA, Mar 2021) with <20% infected. Scaling to 70% naturally would’ve meant 1.5-2 million deaths, assuming no healthcare collapse (which would worsen it).
Effectiveness: Slow and incomplete—variants evolve faster than immunity spreads, and reinfection risks rise (e.g., Omicron evaded prior immunity, Science, Jan 2022).
Grok 3 Beta:
With what data, can any COVID vaccine be shown to be effective and how does it compare with herd immunity?
To evaluate the effectiveness of COVID-19 vaccines, particularly the mRNA ones, we can look at real-world data and clinical trial results. I’ll break this down with the key metrics, then compare it to herd immunity as a strategy.
Data Showing Vaccine Effectiveness
Clinical Trial Data (Efficacy)
Pfizer-BioNTech: The Phase 3 trial (published in NEJM, Dec 2020) showed 95% efficacy in preventing symptomatic COVID-19 after two doses, measured 7 days post-second dose. This was based on 170 confirmed cases among 43,548 participants, with 162 cases in the placebo group vs. 8 in the vaccinated group.
Moderna: Its trial (also NEJM, Dec 2020) reported 94.1% efficacy, with 185 cases in the placebo group vs. 11 in the vaccinated group among 30,420 participants.
These trials focused on preventing symptomatic infection, but severe outcomes were also reduced—e.g., Pfizer had 9 severe cases in placebo vs. 1 in vaccinated.
Real-World Effectiveness
Israel (2021): A study (Lancet, May 2021) of over 1.7 million vaccinated individuals showed Pfizer reduced symptomatic cases by 94% and severe cases by 92% compared to unvaccinated matched controls, even with the Alpha variant circulating.
UK (2021-2022): Public Health England data found two doses of Pfizer or AstraZeneca reduced hospitalization by 90-96% against Delta, per studies like BMJ (Oct 2021).
US CDC Data: A 2021 study across 13 states (MMWR, Sep 2021) showed vaccinated individuals were 5 times less likely to get infected and 10 times less likely to be hospitalized than unvaccinated, pre-Omicron.
Severe Outcomes and Mortality
Qatar (2021): A study (NEJM, Jul 2021) found Pfizer reduced severe disease by 95.7% and death by 96.7% in a real-world setting with high Alpha and Beta variant prevalence.
South Africa (2021): During Omicron, a study (JAMA, Feb 2022) showed two-dose Pfizer reduced hospitalization by 70%, lower than against Delta but still significant.
Waning Immunity and Boosters
Effectiveness against infection drops over time—e.g., Pfizer’s protection fell to ~50% after 5-6 months (Lancet, Oct 2021)—but protection against severe disease holds stronger, around 80-90%. Boosters restore efficacy to 90%+ against severe outcomes, per Israeli data (NEJM, Nov 2021).
Metrics of Effectiveness
Relative Risk Reduction (RRR): Trials show 94-95% reduction in symptomatic cases.
Absolute Risk Reduction (ARR): Smaller, around 0.7-1.1% in trials, due to low baseline infection rates.
Number Needed to Vaccinate (NNV): To prevent one case, ~100-140 people needed vaccination in trial settings, varying by local prevalence.
Hospitalization/Death: Real-world data shows 10-20x lower risk in vaccinated vs. unvaccinated.
Comparison to Herd Immunity
Herd Immunity Basics
Achieved when enough people are immune (via infection or vaccination) to stop sustained transmission.
For COVID-19, estimates pre-vaccines suggested 60-70% immunity needed, based on an R0 of 2.5-3 (e.g., Nature, Jun 2020). With Delta (R0 ~5-7) and Omicron (R0 ~10+), this rises to 80-90%+.
Natural Herd Immunity (Infection-Based)
Data: Sweden’s approach (minimal lockdowns) saw ~20% seroprevalence by mid-2021 (Eurosurveillance, Aug 2021), yet cases surged with Delta. India’s 2021 serosurvey (Lancet Global Health, Sep 2021) showed 67% with antibodies post-Delta wave, but reinfections and Omicron still hit hard.
Cost: Pre-vaccine, the US had ~500,000 deaths by Feb 2021 (JAMA, Mar 2021) with <20% infected. Scaling to 70% naturally would’ve meant 1.5-2 million deaths, assuming no healthcare collapse (which would worsen it).
Effectiveness: Slow and incomplete—variants evolve faster than immunity spreads, and reinfection risks rise (e.g., Omicron evaded prior immunity, Science, Jan 2022).
Vaccine-Driven Herd Immunity
Data: Israel hit ~60% vaccination by mid-2021, reducing cases 10-fold (Nature Medicine, Jul 2021) until Delta. High-vaccination areas (e.g., Vermont, 80%+ by 2022) saw lower per-capita deaths than low-vaccination ones (e.g., Mississippi, ~50%).
Threshold: Vaccines reduce transmission (e.g., 40-60% less with Delta, NEJM, Aug 2021), but breakthrough infections and waning mean 90%+ vaccination might be needed now, per models (PNAS, Dec 2021).
Cost: Far fewer deaths—e.g., US deaths post-vaccine rollout (2021-2023) were ~600,000 over two years vs. 500,000 in one pre-vaccine year, despite variants.
Vaccines vs. Herd Immunity
Speed: Vaccines achieve immunity in weeks; natural spread takes years.
Safety: Vaccines have rare serious side effects (e.g., myocarditis in 1/50,000 young males, JAMA, Jan 2022) vs. millions dying from infection.
Control: Vaccines target high-risk groups first; natural immunity is random and chaotic.
Variants: Vaccines can be updated (e.g., Omicron boosters); natural immunity lags behind evolution.
Outcome: Vaccines cut severe cases by 90%+; natural herd immunity sacrifices lives for partial, unstable protection.
Conclusion
The data—clinical trials, real-world studies, and outcome metrics—shows mRNA vaccines are highly effective at reducing infection, severe disease, and death, with a safety profile vastly superior to letting the virus run unchecked. Herd immunity via infection is a costly, inefficient gamble, proven by high-death regions pre-vaccines and variant-driven resurgences. Vaccines don’t fully stop transmission, so herd immunity’s harder to reach now, but they’re still the better tool—saving lives directly while buying time to adapt to the virus’s evolution.
Data: Israel hit ~60% vaccination by mid-2021, reducing cases 10-fold (Nature Medicine, Jul 2021) until Delta. High-vaccination areas (e.g., Vermont, 80%+ by 2022) saw lower per-capita deaths than low-vaccination ones (e.g., Mississippi, ~50%).
Threshold: Vaccines reduce transmission (e.g., 40-60% less with Delta, NEJM, Aug 2021), but breakthrough infections and waning mean 90%+ vaccination might be needed now, per models (PNAS, Dec 2021).
Cost: Far fewer deaths—e.g., US deaths post-vaccine rollout (2021-2023) were ~600,000 over two years vs. 500,000 in one pre-vaccine year, despite variants.
Vaccines vs. Herd Immunity
Speed: Vaccines achieve immunity in weeks; natural spread takes years.
Safety: Vaccines have rare serious side effects (e.g., myocarditis in 1/50,000 young males, JAMA, Jan 2022) vs. millions dying from infection.
Control: Vaccines target high-risk groups first; natural immunity is random and chaotic.
Variants: Vaccines can be updated (e.g., Omicron boosters); natural immunity lags behind evolution.
Outcome: Vaccines cut severe cases by 90%+; natural herd immunity sacrifices lives for partial, unstable protection.
Conclusion
The data—clinical trials, real-world studies, and outcome metrics—shows mRNA vaccines are highly effective at reducing infection, severe disease, and death, with a safety profile vastly superior to letting the virus run unchecked. Herd immunity via infection is a costly, inefficient gamble, proven by high-death regions pre-vaccines and variant-driven resurgences. Vaccines don’t fully stop transmission, so herd immunity’s harder to reach now, but they’re still the better tool—saving lives directly while buying time to adapt to the virus’s evolution.
Forwarded from The Prisoner's Record (EOJ Always)
Prayer time for Tina Peters starts at 2PM ET each day this week.
Dial in and listen, or participate.
Be sure to mute yourself when not speaking.
(669)274-9260
Dial in and listen, or participate.
Be sure to mute yourself when not speaking.
(669)274-9260